A carregar...
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
BACKGROUND: First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the advent of target-specific and highly act...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7254109/ https://ncbi.nlm.nih.gov/pubmed/32273346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000213 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|